Prognostic factors in cancer of unknown primary site

Tumori

Volumn 96, Issue 1, 2010, Pages 111-116

  Fernandez Cotarelo, Maria Jose ^a   Guerra Vales, Juan Manuel ^b   Colina, Francisco ^b   De La Cruz, Javier ^b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Prognosis; Survival; Tumor metastasis; Unknown primary tumors

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGISTRY; CANCER SURVIVAL; CONFIDENCE INTERVAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UNIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, UNKNOWN PRIMARY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 77950812048     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600118     Document Type: Article

References (36)

1. Hainsworth JD, Greco FA: Treatment of patients with cancer of an unknown primary site. N Engl J Med, 329: 257-263, 1993.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer, 39: 1990-2005, 2003.
3. Van de Wouw AJ, Janssen-Heijnen MLG, Coeberg JWW, Hillen HFP: Epidemiology of unknown primary tumours: incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer, 38: 409- 413, 2002.
4. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber AN, Lenzi R, Frost P: Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol, 12: 1272-1280, 1994.
5. Le Chevalier T, Cvitkovic E, Caille P: Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med, 148: 2035-2039, 1988.
6. Al-Brahim N, Ross C, Carter B, Chorneyko K: The value of post-mortem examination in cases of metastasis of unknown origin. 20 year retrospective data from a tertiary care center. Ann Diagn Pathol, 9: 77-80, 2005.
7. Mayordomo JI, Guerra JM, Guijarro C, García-Prats MD, Gómez A, López-Brea M, Gonzalez R, Hergueta P, López- Pino MA, Martínez-Tello F, Cortés-Funes H: Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori, 79: 321-324, 1993.
8. NCCN clinical practice guidelines in oncology. Occult primary, Version 2008. National Comprehensive Cancer Network, Inc. Available from http://www.nccn.org/professionals/ physician-gls/PDF/occult.pdf [Accessed March 4, 2008].
9. Penel N: Pronostic et possibilités thérapeutiques des métastases inaugurales. Presse Med, 32: 997-1004, 2003.
10. ESMO Guidelines Task Force: ESMOminimumclinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol, 16 (Suppl 1): i75-i76, 2005.
11. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, Merrouche Y, Ganem G, Kaminsky MC, Negrier S, Perol M, Laforêt C, Bedossa P, Bertrand G, Coindre JM, Fizazi K: Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer, 89 (Suppl 1): S59-S66, 2003. (Pubitemid 37076150)
12. Antuña Egocheaga A, López GonzálezML, Lobo Fernández J, Fernández Bustamante J, Moris de la Tassa J, Cueto Espinar A:Diagnostic protocol for unknown primary cancers. Review of 157 cases. AnMed Interna (Madrid), 19: 405-408, 2002.
13. Altman E, Cadman E: An analysis of 1539 patients with cancer of unknown primary site. Cancer, 57: 120-124, 1986.
14. Yakushiji S, Ando M, Yonemori K, Kohno T, Schimizu C, Katsumata N, Fujiwara Y: Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol, 11: 421-425, 2006.
15. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palestry JA: Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg, 194: 833-838, 2007.
16. Maiche AG: Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol, 16: 26-29, 1993.
17. Ponce Lorenzo J, Segura Huerta R, Díaz Beveridge, Giménez Ortiz A, Aparisi Aparisi F, Fleitas Kanonnikoff T, Richart Aznar P, de la Cueva Sapiña H, Montalar Salcedo J: Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol, 9: 452-458, 2007.
18. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB: Cervical lymph nodemetastases fromunknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol, 55: 121-129, 2000.
19. Argiris A, Smith SM, Stenson K, Mittal BB, Pelzer HJ, Kies MS, Haraf DJ, Vokes EE: Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary. Ann Oncol, 14: 1306-1311, 2003. (Pubitemid 37039060)
20. Muñoz del Castillo F, Jurado Ramos A, Navarro Ortiz F, López Villarejo P: Metastatic neck adenopathies without known primary tumor. Incidence study 1996-2001. An Otorrinolaringol Ibero Am, 30: 489-500, 2003.
21. Hess KR, AbbruzzeseM, Lenzi R, RaberMN, Abbruzzese JL: Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res, 5: 3403-3410, 1999.
22. Hainsworth JD, Spigel D, Litchy S, Greco A: Phase II trial of paclitaxel, carboplatin and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol, 24: 3548-3554, 2006.
23. Van der Gaast A, Verweij J, Planting AST, HopWC, Stoter G: Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol, 13: 1720-1725, 1995.
24. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P,Ychou M: Hepatic metastases from carcinomas of unknown primary site: experience of the Montpellier Cancer Center. Gastroenterol Clin Biol, 29: 1224-1232, 2005.
25. Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P: Métastases hépatiques de site primitif inconnu. Bull Cancer, 78: 725-736, 1991.
26. Seve P, Ray-Coquard I, Trillet-LenoirV, SawyerM, Hanson J, Broussolle C, Negrier S, Dumotet C,Mackey JR: Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer, 107: 2698-2705, 2006.
27. Trivanovic D, Petkovic M, Stimac D: Low serum albumin levels and livermetastasis are powerful prognosticmarkers for survival in patients with carcinomas of unknown primary site. Cancer, 109: 2623. Author reply: 2624, 2007.
28. Shaw PHS, Adams R, Jordan C, Crosby TDL: A clinical review of the investigation andmanagement of carcinoma of unknown primary in a single cancer network. Clin Oncol, 19: 87-95, 2007.
29. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A,MerroucheY, Laplanche A, Fizazi K: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol, 20: 4679-4683, 2002.
30. Pavlidis N, Kalef-Ezra J, Briasoulis E, Skarlos D, Kosmidis P, Saferiadis K, Bairaktari E, Bafaloukos D, Maravegias A, Theoharis D, Fountzilas G: Evaluation of six tumormarkers in patients with carcinoma of unknown primary. Med Pediatr Oncol, 22: 162-167, 1994.
31. Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, Samantas E, Pavlidis N: Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? Acta Oncol, 44: 155-160, 2005.
32. Milovic M, Popov I, Jelic S: Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit, 8: 25-30, 2002.
33. Martin A, Corte MD, Alvarez AM, Rodríguez JC, Andicoechea A, Bongera M, Junquera S, Pidal D, Allende T, Muniz JL, Vizoso F: Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res, 26: 3965-3971, 2006.
34. Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Altoriai G: Prognostic value ofmonitoring tumourmarkers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer, 26: 81, 2006.
35. Blaszyk H, Hartmann A, Björnsson J: Cancer of unknown primary: clinicopathologic correlations. APMIS, 111: 1089-1094, 2003.
36. Seve P, Sawyer M, Hanson J, Brousolle C, Dumontet C, Mackey JR: The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population based study. Cancer, 106: 2058-2066, 2006.